Transforming growth factor-b (TGF-b) is a key driver for liver fibrogenesis. TGF-b must be activated in order to function. Plasma kallikrein (PLK) is a TGF-b activator that cleaves the latency-associated protein (LAP) between arginine 58 and lysine 59 residues and releases active TGF-b from the latent TGF-b-LAP complex. Thus, the generation of two LAP degradation products, ending at arginine 58 
Introduction
Liver fibrosis is a wound-healing process characterized by the excessive accumulation of extracellular matrixes (ECMs) that results from a disturbed balance between fibrogenesis and fibrolysis [1, 2] . Because early fibrosis is often asymptomatic and can be reversed with appropriate treatment, the accurate assessment of fibrogenic activity is important for tracking and predicting disease progression and monitoring responses to antifibrotic therapies [3, 4] . Several serum biomarkers and ultrasoundbased elastography are currently available for the noninvasive assessment of liver fibrosis [5, 6] . A liver biopsy is invasive but remains the gold standard for evaluating fibrosis, which is generally diagnosed based on an increased ECM deposition [6] .
However, most methods basically reflect the already-accumulated ECM, and not ongoing ECM synthesis. Therefore, the development of a reliable method of assessing liver fibrogenesis, the initial event of fibrosis, is urgently needed for the management of patients with chronic liver disease (CLD).
Transforming growth factor-b (TGF-b) is a central regulator of liver fibrogenesis [4, 7] . TGF-b is secreted from liver cells in a latent form in which it is complexed with latency-associated protein (LAP) and latent TGF-b binding protein (LTBP) (Fig. 1 ) [8] . Several factors, including integrins, thrombospondin-1 (TSP-1), and proteases, modulate the conformation of LAPs and release active TGF-b from the latent complex in a process called TGF-b activation ( Fig. 1) [8] . The resultant active TGF-b induces the transdifferentiation of quiescent hepatic stellate cells (HSCs) into myofibroblast-like activated HSCs (aHSCs), in which TGF-b-dependent Smad-signaling pathways are activated to stimulate ECM synthesis [1, 2, 3, 4, 7] . Although the abundance of active TGF-b in plasma and tissues appears to be an ideal biomarker that directly reflects liver fibrogenesis, its half-life in plasma is reported to be only 2e3 minutes, which makes it difficult to accurately measure the level of TGF-b [9] .
Recently, Hara et al. have demonstrated that plasma kallikrein (PLK) cleaves LAP between the arginine 58 and lysine 59 residues to cause TGF-b activation [10] . They further showed that this event occurs in the progression of liver fibrosis in rodent models as well as in patients, by detecting the N-terminal side LAP degradation product ending at arginine 58 (R 58 /LAP-DP) in the fibrotic liver using a specific antibody that they generated [10] . Since R 58 /LAP-DP is covalently bound to the LTBP that is anchored to ECMs [8] , the degradation products remain in tissues even after the release of active TGF-b, thereby making it possible to map TGF-b activation in the liver. The other by-product, the C-terminal side LAP-DP beginning from lysine 59 (L 59 /LAP-DP), is released into the blood circulation after TGF-b activation, and its plasma levels can be measured with an enzyme-linked immunosorbent assay (ELISA) [11] . In animal models of liver fibrosis, the plasma L 59 /LAP-DP abundance was well correlated with the expression of a-smooth muscle actin (a-SMA), an aHSC marker, in the liver tissue prior to the excessive deposition of ECMs [11] .
In addition, L 59 /LAP-DPs are stable in the blood, with a half-life of approximately 8 hours [11] . These data support the potential utility of R 58 and L 59 /LAP-DPs as surrogate markers for PLK-dependent TGF-b activation in the liver. However, there have been very few studies focusing on the significance of TGF-b activation in the pathogenesis of liver fibrosis in patients.
In the present study, we evaluated the PLK-mediated TGF-b activation in patients with CLD by measuring the abundance of R 58 and L 59 /LAP-DPs in the liver tissues and plasma, respectively. We further examined the usefulness of the LAP-DPs as biomarkers to detect liver fibrogenesis and to monitor the clinical course of CLD.
Materials and methods

Patients
This study included a total of 234 patients, who had received treatment or follow-up care for CLD at Jikei University Hospital between 2007 and 2015. 
Liver histology
Liver biopsy specimens were fixed in 10% neutral buffered formalin and paraffinembedded. Serial 3-mm-thick sections were cut from formalin-fixed paraffin-embedded (FFPE) tissue specimens and subjected to hematoxylin-eosin and Masson's trichrome staining for use in histological observation.
Masson's trichrome staining stains collagen, including type I collagen (Col I), which is overproduced and a major component of the ECM in fibrotic liver (Fig. 2) .
Histological grading and staging of NAFLD or chronic viral hepatitis were performed for each biopsy specimen according to the non-alcoholic steatohepatitis (NASH) Clinical Research Network criteria or the METAVIR scoring system, respectively (see Table 2 for details) [12, 13, 14] .
Antibodies
Mouse monoclonal antibodies against R 58 /LAP-DP (R 58 antibody) and L 59 /LAP-DP (L 59 antibody) were generated in S. Kojima's laboratory [10] . Mouse monoclonal antibodies to detect a-SMA and cellular retinol-binding protein-1 (CRBP-1) were purchased from Dako (Glostrup, Denmark) and Santa Cruz Biotechnology (Dallas, TX), respectively. A rabbit polyclonal antibody specific for Col I was purchased from Abcam (Cambridge, UK). 
Immunohistochemistry
Serial 3-mm-thick sections were cut from FFPE tissue specimens for immunohistochemical staining. After deparaffinization, the sections were microwavetreated for 10 min at 95 C for antigen retrieval and then incubated with 0.3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase activity. The sections were treated with R 58 antibody (1 mg/mL) or L 59 Osaka, Japan).
The R 58 /LAP-DP expression was quantitatively evaluated by measuring the R 58 / LAP-DP-positive areas in the entire region of each liver biopsy specimen and was represented as "% R 58 (þ) Area".
ELISA
The sandwich ELISA for L 59 /LAP-DPs was performed according to the procedure described in a previous report [11] . Briefly, Nunc 96-well Maxisorp plates (Thermo Fisher Scientific, Waltham, MA) were coated with L 59 antibody (20 mg/mL) in Trisbuffered saline overnight. After blocking, plasma samples were added and incubated overnight, followed by sandwiching with 1 mg/mL biotin-conjugated anti-LAP antibody for 3 h. After another 3 h of incubation with streptavidin-conjugated alkaline phosphatase (Jackson ImmunoResearch Laboratories, West Grove, PA), 4-nitrophenylphosphate disodium salt hexahydrate dissolved in diethanolamine buffer was added to each well, and the color development of the subsequent reaction was measured at 405 nm on a microplate reader. Recombinant human LAP (TGF-b1) protein (R&D Systems, Minneapolis, MN) digested with human PLK (Merck Millipore, Burlington, MA) was used for creating a standard curve.
Interferon (IFN)-based treatment for CHC
Nineteen CHC patients received a combined pegylated IFN-a (PEG-IFN-a) and ribavirin (RBV) therapy basically for 12 months. The patients were categorized into two groups in accordance with their virological responses as follows: sustained responders (SRs), continuously undetectable HCV RNA for 6 months or longer after the end of treatment, and non-responders (NRs) with detectable HCV RNA during or after treatment.
Statistical analyses
Quantitative data are shown as the mean AE standard deviation (SD). The MannWhitney U test or Kruskal-Wallis test was employed to evaluate differences in the abundance of LAP-DPs between two groups or more than two groups, Table 1 . There were no statistically significant differences regarding age, gender, or the serum levels of liver enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), between the patients with NAFLD and those with viral hepatitis. The body mass index (BMI), serum concentrations of g-glutamyltransferase (GGT), total cholesterol (TC), and triglyceride (TG), and the blood hemoglobin A1c (HbA1c) level in the NAFLD patients were significantly higher than those in the viral hepatitis patients, showing that the development of NAFLD is strongly associated with disturbances in lipid and glucose metabolism. Significant reductions in serum albumin (ALB) and the number of platelets (PLTs), as well as the elevation of serum fibrosis markers, hyaluronic acid (HA), and type IV collagen (Col IV), were observed in patients with viral hepatitis. However, the serum levels of these fibrosis markers in the two patient groups did not differ to a statistically significant extent.
The histological findings of liver biopsy specimens from the patients are presented in Table 2 . In contrast to the differences in the laboratory characteristics (Table 1) , there appeared to be no obvious differences in the distribution of the grades of inflammation or the stages of fibrosis between the two patient groups.
The expression and distribution of R 58 /LAP-DP in the liver tissue of patients with NAFLD
Liver biopsy specimens from patients with NAFLD were subjected to Masson's trichrome staining, which stains Col I (Fig. 2) , and immunostaining with an antibody specific for R 58 /LAP-DP or a-SMA, a marker of aHSCs and myofibroblasts ( Fig. 3) . In liver specimens from living donors (negative controls; NC) and patients with stage 0 fibrosis, no parenchymal regions were specifically stained with Masson's trichrome or a-SMA antibody, with the exception of the portal areas containing vessels and connective tissues (Fig. 3 , top panels and second panels from the top). Mild steatosis was only present in liver tissue from patients with stage 0 fibrosis; however, no apparent expression of R 58 /LAP-DP was observed in the liver parenchyma. Negligible non-specific staining of red blood cells by R 58 antibody was detected under high-magnification (arrowheads). In biopsy specimens from patients with stage 1B fibrosis, mild steatosis and fibrosis were observed in centrizonal regions, while R 58 /LAP-DP was robustly expressed throughout hepatic lobules (Fig. 3 , third panels from the top). The R 58 /LAP-DP expression was mostly detected along the sinusoidal walls and on adjacent hepatocytes by observation under higher magnification. Obvious periportal and bridging fibrosis was present in liver specimens from fibrosis stage 2 and 3 patients, respectively (Fig. 3 , fourth and fifth panels from the top). The R 58 /LAP-DP expression was globally reduced and primarily distributed in and around the regions of fibrosis. Under high magnification, R 58 /LAP-DP signals were mainly detected along sinusoidal walls and on the adjacent fibrous matrices (arrows).
To more precisely assess the expression and localization of R 58 /LAP-DP in the liver tissue, we performed double-immunostaining of the liver biopsy specimens obtained from NAFLD patients with stage 1B and 3 fibrosis (Fig. 4) . The sections were coimmunostained with antibodies against R 58 /LAP-DP and CRBP-1, which is a marker specific for both aHSCs and quiescent HSCs [15, 16] . Similar to the results shown in Fig. 3 , R 58 /LAP-DP was markedly expressed along the sinusoidal walls containing CRBP-1-positive HSCs ( Fig. 4B and D, arrows) . The R 58 /LAP-DP expression was also detected on some hepatocytes in the liver tissue from a fibrosis stage 1B patient (Fig. 4B, arrowheads) .
Collectively, our histological observation of NAFLD liver tissues showed that R 58 / LAP-DP was robustly expressed on and around sinusoidal cells before the completion of liver fibrosis, suggesting that the expression of R 58 /LAP-DP may reflect fibrogenic activity in the early stages of NAFLD. 
The expression and distribution of R 58 /LAP-DP in the liver tissue of patients with chronic viral hepatitis
We next examined the liver biopsy specimens from patients with chronic viral hepatitis using the same method as for NAFLD (Fig. 5) . In specimens from patients with a METAVIR score of F0, R 58 /LAP-DP was marginally expressed within the hepatic lobules and was found to be mainly localized along the sinusoidal walls by observation under high magnification (Fig. 5A, top panels) . In biopsy specimens from F1 stage patients, mild periportal fibrosis was observed with Masson's trichrome and a-SMA staining (Fig. 5A , second panels from the top). R 58 /LAP-DP was detected extensively throughout the liver parenchyma, but its expression was weaker and more scattered than that in NAFLD livers with a comparable stage of fibrosis. R 58 /LAP-DP signals were largely observed along the sinusoidal walls but were rarely detected on hepatocytes by high-magnification imaging. Interestingly, the distribution of R 58 /LAP-DP was quite different from that of a-SMA in this stage.
Apparent periportal and septal fibrosis with moderate necroinflammation was observed in biopsy specimens from F2 and F3 stage patients (Fig. 5A , third and fourth panels from the top). Similar to NAFLD livers, the overall R 58 /LAP-DP expression was attenuated in comparison to that in F1 tissues and was predominantly detected in and around the regions of fibrosis. The R 58 /LAP-DP signals appeared to be less associated with necroinflammation. High-magnification images of F2 and F3 specimens showed that R 58 /LAP-DP was mainly expressed in sinusoidal cells and adjacent fibrous matrices. Double-staining experiments further demonstrated that R 58 /LAP-DP-positive sinusoidal cells were present around and between the a-SMA-positive fibrous regions, as though the cells mediated the formation of septal fibrosis ( Fig. 5B and C) . These results suggest that R 58 /LAP-DP might be a histological marker for evaluating the fibrogenic potential in the early stages of liver fibrosis.
3.4.
The relationship between PLK-dependent TGF-b activation and the histological features of the liver tissue of NAFLD and chronic viral hepatitis patients
Our histological observations showed that PLK-mediated TGF-b activation was obviously detected in the early stages of liver fibrosis, while TGF-b signaling has been reported to be associated not only with fibrosis but also with the lipid accumulation or inflammatory cell infiltration [17] . To more accurately validate the significance of PLK-dependent TGF-b activation in the progression of CLDs, we examined the relationship between the R 58 /LAP-DP expression and the histological findings in all biopsy samples. A quantitative evaluation of the R 58 /LAP-DP expression was performed as shown in the Materials and methods. Distinct R 58 /LAP-DP deposition was frequently observed at the edge of biopsy tissues, regardless of the histological findings, presumably resulting from tissue crushing by a needle biopsy or non-specific staining by R 58 antibody (Fig. 6A, left panel, arrows) . To eliminate this effect, areas less than 100 mm from the edge were excluded from measurement (Fig. 6A, right panel) .
The percentages of R 58 /LAP-DP-positive areas in all biopsy specimens from patients with NAFLD or viral hepatitis ranged from 1.00% to 27.1% (average, 6.20%). In contrast, the percentages in the biopsy specimens from the two living donors were 1.29% and 1.88%, respectively (average, 1.58%). In NAFLD liver tissues, the extent of the R 58 /LAP-DP expression did not show a statistically significant association with the scores for steatosis, lobular inflammation, hepatocellular ballooning, or the NAFLD activity score (NAS) (Fig. 6B ). Regarding the relationship with the fibrosis stages, the R 58 /LAP-DP expression was the highest at the 1B stage; more than 10% of the entire section was R 58 /LAP-DP-positive (Fig. 6B, "Fibrosis" panel) .
The expression clearly decreased at stages 2 and 3, and especially, a statistically significant difference was observed between stages 1B and 2 (P < 0.05). In the liver tissue specimens with viral infection, there were no marked differences in the R 58 / LAP-DP expression among the grades of inflammation (Fig. 6C, left panel) . Similar to the results obtained from NAFLD liver tissue, the R 58 /LAP-DP expression at the F1 stage was higher than that at any other stages of fibrosis, and the expression decreased at the F2 and F3 stages. A statistically significant difference was found between the F1 and F2 stages (Fig. 6C , right panel; P < 0.05). Interestingly, the percentages of R 58 /LAP-DP-positive areas were substantially higher in the liver tissues of NAFLD patients than in those of patients with viral infection (7.49 AE 5.58% versus 4.08 AE 2.50%, mean AE SD; P < 0.01) (Fig. 6D) , although there was no marked difference in the distribution of fibrosis stages between the two patient groups ( Table 2 ).
These statistical analyses provide evidence that PLK-dependent TGF-b activation is associated with liver fibrosis and it occurs in the early stages, regardless of the causes of CLD. However, there appears to be a difference in the extent of TGF-b activation among different etiologies of CLD. Table 3 . The female ratio was significantly higher among patients with other liver diseases (especially AIH and PBC) than in those with CHB or CHC. The age distributions of the three patient groups were widely different from one another. With respect to blood markers and tests closely linked to the liver function or tumorigenesis, differences in the serum levels of ALB, AST, ALT, GGT, or protein induced by vitamin K absence-II (PIVKA-II) were not pronounced, but the serum a-fetoprotein (AFP) levels, PLT counts, and the prothrombin time (PT) differed significantly among the three groups. The significant elevation of the serum levels of fibrosis markers, such as HA and Col IV, and the fibrosis index based on the four factors (FIB-4) [18] was observed in patients with CHC. There was no significant difference in the plasma L 59 /LAP-DP concentration among the three groups. Table 4 . Although the inflammatory activities of the CHB patients' livers were significantly more severe than those of the CHC patients' livers, no obvious difference in the distribution of the fibrosis stages was found between the two patient groups. The average plasma concentration of L 59 /LAP-DP in patients with inflammatory grade 1 was higher than that in patients with other grades, but there was no significant difference in the distribution of the plasma abundance between any patient group with a different grade (Fig. 7B) . A similar trend was observed among patients with different fibrosis stages; that is, the average plasma level of L 59 /LAP-DP was the highest in patients with stage 1 (Fig. 7C) , consistent with the results of the R 58 /LAP-DP expression in the patients' livers ( Fig. 6B and C, "Fibrosis" panels).
The relationship between the plasma L 59
/LAP-DP level and factors associated with the liver function, fibrosis, or carcinogenesis in patients with CLD
To explore the possible use of the plasma L 59 /LAP-DP abundance as a biomarker for liver fibrosis, its relationship with factors related to the liver function was examined (Fig. 8AeH) . We further tested whether the plasma L 59 /LAP-DP concentration was related to serum biomarkers that are closely linked to liver fibrosis or cancer. There was no obvious association between the plasma L 59 /LAP-DP level and the serum abundance of HA, Col IV, AFP, or PIVKA-II. However, a weak but nonnegligible positive correlation was found between the plasma L 59 /LAP-DP level and the FIB-4 value (Pearson's r ¼ 0.156, P ¼ 0.032) (Fig. 9AeE) . These results suggest that the abundance of L 59 /LAP-DP is associated with liver fibrosis because serum ALB and FIB-4 values are known to have a close relationship to the progression of liver fibrosis [5, 18, 19, 20] . However, the role of L 59 /LAP-DPs in the development of liver fibrosis might be different from the roles of HA and Col IV, which are widely used as serum fibrosis markers. for CHC [21, 22, 23] . To clarify whether the plasma L 59 /LAP-DP abundance serves as a predictive marker for viral responses to antiviral treatment, its association with treatment outcomes was examined in CHC patients who received combined PEG-IFN-a and RBV treatment. As shown in Fig. 10A , the plasma L 59 / CHB, chronic hepatitis B; CHC, chronic hepatitis C; w/o, without. a The difference in the distribution of the grades of inflammation or the stages of fibrosis between the two patient groups (CHB versus CHC) was statistically analyzed with a chi-squared test.
LAP-DP level at 6 months after the beginning of treatment was lower in comparison to before treatment (82.67 AE 54.17 pM versus 114.9 AE 81.06 pM, mean AE SD), but the difference was not statistically significant (P ¼ 0.11). The plasma concentrations of L 59 /LAP-DP in SRs and NRs prior to treatment were 129.1 AE 72.25 pM and 84.07 AE 97.26 pM (mean AE SD), respectively, and those after 6 months of treatment were 76.60 AE 47.78 pM and 95.84 AE 69.13 pM (mean AE SD), respectively. There were no significant differences in the plasma L 59 /LAP-DP levels before or after the initiation of treatment between SRs and NRs. Concerning the relationship between changes in the plasma L 59 /LAP-DP concentration during IFN-based treatment and the treatment outcomes, 11 of 13 SRs showed a decreased plasma L 59 /LAP-DP abundance at 6 months after the initiation of treatment, while five of 6 NRs exhibited an increase. There was a statistically significant difference in the SR-to-NR ratio between the two patient groups categorized based on changes in the plasma L 59 /LAP-DP level (Fig. 10B ). To more precisely assess the predictive value of L 59 /LAP-DPs in relation to the treatment outcome, the time-course changes in the plasma L 59 /LAP-DP level were analyzed in individual patients. A representative case from the SR group demonstrated that the plasma L 59 /LAP-DP abundance decreased rapidly and remained low after the initiation of combined PEG-IFN-a and RBV therapy, whereas more delayed and incomplete declines were observed in the serum levels of HA and AFP (Fig. 10C) , both of which are reported to be serum markers for predicting the outcomes of treatment in patients with CHC [21, 22, 23, 24] . In a representative case from the NR in which serum HCV RNA reappeared just after the end of treatment, the plasma L 59 /LAP-DP level fluctuated and was gradually elevated even during treatment, although the serum concentrations of HA and AFP were decreased after the beginning of treatment (Fig. 10D ).
These results suggest that the plasma L 59 /LAP-DP abundance and its changes are useful as blood biomarkers for predicting the outcomes of IFN-based treatment for CHC. Its predictive accuracy, including sensitivity and reliability, could be higher in comparison to serum HA and AFP.
Discussion
In the current study, we examined the abundance of R 58 and L 59 /LAP-DPs in patients with CLD and revealed the significance of PLK-dependent TGF-b activation in the early stages of liver fibrosis. The robust expression of R 58 /LAP-DP was detected in and around sinusoidal cells before the development of a-SMA-positive fibrous regions, suggesting that PLK-dependent TGF-b activation may be the initial event that induces liver fibrogenesis. A previous study showed that R 58 / LAP-DP was mainly detected in a-SMA-positive areas in liver tissues from both rodent models and patients with advanced fibrosis [10] . This was consistent with our histological findings at fibrosis stages 2 and 3, but not at earlier stages, in which the distribution of R 58 /LAP-DP was different from that of a-SMA (Figs.
3 and 5). Our closer immunohistochemical analysis further revealed that R 58 / LAP-DPs were mostly expressed in a-SMA-negative sinusoidal cells existing around and between the a-SMA-positive fibrous areas, as though the R 58 /LAP-DP expression predicted the subsequent progression of fibrosis ( Fig. 5B and C) .
These results suggest that the R 58 /LAP-DP expression can reflect the active TGF-b production that causes liver fibrogenesis and may function as a predictive marker of the fibrogenic activity at the early stages of fibrosis. This was the case with the relationship between the plasma L 59 /LAP-DP level and the fibrosis stage in patients. The average plasma concentration of L 59 /LAP-DP was highest in patients with stage 1; however, its difference among patient groups with different fibrosis stages was not so pronounced (Fig. 7C) . The contribution of PLKmediated TGF-b activation to fibrosis in the early stages was also reported in a previous study using mouse models of liver fibrosis [11] .
The latent TGF-b complex secreted from cells is typically tethered to the ECM via LTBPs [8] . PLK or other molecules, including integrins, TSP-1, and proteases, such as matrix metalloproteinases, are known to liberate active TGF-b from the LAP in a specific manner [8] . [28, 29] . In addition, studies have demonstrated that GARP is also present on liver sinusoidal endothelial cells and HSCs [30, 31] . Thus, the R 58 /LAP-DP expression on the cells in our study may reflect the binding of the latent TGF-b complex to the cell surface through GARP and the subsequent PLK-dependent TGF-b activation there.
Our quantitative analysis of the R 58 /LAP-DP expression revealed that NAFLD patients had a significantly higher expression of R 58 /LAP-DP in their liver tissue than patients with chronic viral hepatitis, although the levels of serum markers of liver fibrosis were higher in the latter group (Table 1 and Fig. 6D ). This finding may be due to differences in the involvements of PLK and TGF-b in the progression of the two liver diseases. Recently, the endotoxin-induced stimulation of Kupffer cells has been proposed as an important initiating event leading to the onset and progression of NASH [32] . Stimulated Kupffer cells produce tumor necrosis factor-a, which enhances the PLK activity on the HSC surface [33] , thereby highlighting the PLK-dependent activation of latent TGF-b in the liver of NAFLD/NASH patients. Conversely, TGF-b signaling events have been reported to show a lower correlation with the fibrosis stage in patients with HCV infection than in those with NAFLD [25] . Instead, the cytokine interleukin-13, which is known to be involved in the fibrosis of diverse organs, was shown to induce HSC activation directly, and its expression was significantly correlated with the severity of liver fibrosis in HCV-infected patients [25] . These reports suggest that the impact of TGF-b signaling may differ depending on the cause of liver diseases and that it may be smaller in cases of HCV-associated liver fibrosis than in NASH-related fibrosis.
The plasma concentration of L 59 /LAP-DP was significantly correlated with the serum ALB level and the FIB-4 value (Figs. 8G and 9C), both of which are indirect markers of liver fibrosis [5, 18, 19, 20] , suggesting the association of the plasma L 59 / LAP-DP abundance with the development of liver fibrosis. In contrast, the plasma level of L 59 /LAP-DP showed no correlation with the concentrations of direct serum biomarkers of liver fibrosis, such as HA and Col IV ( Fig. 9A and B) , presumably due to the different roles of these two types of markers in the progression of liver fibrosis. The L 59 /LAP-DPs are a surrogate marker for PLK-dependent TGF-b activation that induces liver fibrogenesis, and the plasma level increased in the early stages of liver fibrosis but decreased in the advanced stages, while the serum abundance of HA and
Col IV is positively correlated with the degree of ECM accumulation and increases with the progression of liver fibrosis [34, 35] . Thus, L 59 /LAP-DPs will serve as a novel blood marker to evaluate the fibrogenic activity in the liver, independently of widely used serum fibrosis markers.
Studies demonstrated that the TGF-b level after IFN-based treatment was significantly decreased in comparison to before treatment in CHC patients [36, 37, 38, 39] . However, it is controversial whether the abundance of TGF-b or its changes during treatment are associated with virological responses [36, 37, 38, 39, 40, 41] . In most of the studies, the amounts of total TGF-b, including latent LAP-TGF-b complexes, were measured, but the TGF-b activation in the liver was not evaluated precisely [36, 37, 38, 39, 40, 41] . We focused on the PLK-dependent TGF-b activation in this study and examined its association with viral responses to IFN-based therapy by measuring the plasma L 59 /LAP-DP level. The mean concentration of L 59 /LAP-DP in 19 patients with CHC showed a tendency to decrease after the initiation of treatment with PEG-IFN-a and RBV (Fig. 10A) . Furthermore, the changes in the plasma L 59 /LAP-DP level during treatment were significantly associated with virological responses (Fig. 10B) , although the plasma level itself before and during treatment (after 6 months of treatment) did not predict the treatment outcome (Fig. 10A ).
These results are consistent with previous reports investigating the relationship between the TGF-b level and the viral response to IFN-based treatment for CHC [36, 40, 41] . TGF-b exerts a proviral effect on HCV replication dependently or independently of its inhibitory actions on IFN signaling [42, 43] . Thus, the bioactive TGF-b level may be positively correlated with the ability of HCV to propagate. Little is known about the mechanisms responsible for the inhibitory effects of IFN-a (plus RBV) on TGF-b activation, except that it inhibits the proliferation of HSCs [44] .
Since HCV is reported to increase the TGF-b expression through the induction of reactive oxygen species [45] , anti-HCV treatment may also contribute to the suppression of TGF-b activation. In patients with no decreases in their plasma L 59 / LAP-DP level during IFN-based therapy, the inhibitory effects of IFN-a on TGFb activation and viral propagation could be attenuated due to the possible involvement of host or virus factors in IFN signaling, thus presumably leading to an increase in the number of NRs.
The potential utility of R 58 and L 59 /LAP-DPs as histological and biochemical surrogate markers for the PLK-mediated TGF-b activation will allow for appropriate and prompt interventions for early-stage liver fibrosis. Furthermore, since L 59 /LAP-DP could be a highly sensitive and independent blood marker of liver fibrogenesis, its measurement in combination with other serum fibrosis markers may contribute to the accurate diagnosis and appropriate management of CLD. The recent advent of direct-acting antivirals (DAAs) has led to a major advance in the treatment of hepatitis C, and antiviral therapy with DAAs is now widely used for hepatitis C patients in the world. Thus, we are now studying whether the dynamics of PLK-dependent TGF-b activation observed in patients under IFN-based treatment is also reproduced in those who receive DAA therapy.
